- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
June 29th, 2008
A drug developed using nanotechnology and a fungus that contaminated a lab experiment may be broadly effective against a range of cancers, United States researchers reported on Sunday.
The drug, called lodamin, was improved in one of the last experiments overseen by Dr Judah Folkman, a cancer researcher who died in January. Dr Folkman pioneered the idea of angiogenesis therapy - starving tumours by preventing them from growing blood supplies.
Lodamin is an angiogenesis inhibitor that Dr Folkman's team has been working to perfect for 20 years. Writing in the journal Nature Biotechnology, his colleagues say they developed a formulation that works as a pill, without side-effects.
They have licensed it to SynDevRx, a privately held Cambridge, Massachusetts biotechnology company that has recruited several prominent cancer experts to its board.
Tests in mice showed it worked against a range of tumours, including breast cancer, neuroblastoma, ovarian cancer, prostate cancer, brain tumours known as glioblastomas and uterine tumours.
|Related News Press|
Arrowhead Pharmaceuticals to Webcast Fiscal 2016 Year End Results December 7th, 2016
Fast, efficient sperm tails inspire nanobiotechnology December 5th, 2016
UTSA study describes new minimally invasive device to treat cancer and other illnesses: Medicine diffusion capsule could locally treat multiple ailments and diseases over several weeks December 3rd, 2016
Scientists track chemical and structural evolution of catalytic nanoparticles in 3-D: Up-close, real-time, chemical-sensitive 3-D imaging offers clues for reducing cost/improving performance of catalysts for fuel-cell-powered vehicles and other applications December 8th, 2016